{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:42:05Z","timestamp":1782236525661,"version":"3.54.5"},"reference-count":32,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T00:00:00Z","timestamp":1257379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> To evaluate the levels of antimony in plasma and skin of patients being treated with pentavalent antimonials (Glucantime<jats:sup>\u00ae<\/jats:sup>) and their relationship with side effects.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> We evaluated 19 patients treated endovenously at the conventional dose (20\u2003mg Sb<jats:sup>v<\/jats:sup>\/kg\/day), two at a smaller dose (5\u2003mg Sb<jats:sup>v<\/jats:sup>\/kg\/day) and three treated intralesionally (up to 4.0\u2003ml\/week). During treatment, patients underwent periodic blood exams and were interviewed weekly about the incidence of adverse symptoms. The levels of antimony in plasma and skin samples were determined by Inductively Coupled Plasma with Mass Spectrometry (ICP\u2010MS).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The patients under conventional treatment presented a mean initial antimony plasma concentration of 3.39\u2003\u03bcg\/l; at the end of treatment, these levels were 0.21 before Glucantime<jats:sup>\u00ae<\/jats:sup> application and 125.8\u2003mg after Glucantime<jats:sup>\u00ae<\/jats:sup> application. The mean antimony level in their skin at the end of the treatment was 9.24\u2003\u03bcg\/g. The main adverse symptoms were arthralgia and myalgia; laboratory results showed mainly lymphocytosis and eosinophilia.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> We found some significant correlations between antimony concentrations, adverse symptoms and laboratory alterations, strengthening the hypothesis of a dose\u2013dependent relationship between antimony concentration in plasma and skin and side effects.<\/jats:p>","DOI":"10.1111\/j.1365-3156.2009.02408.x","type":"journal-article","created":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T13:02:10Z","timestamp":1257426130000},"page":"1515-1522","source":"Crossref","is-referenced-by-count":26,"title":["Antimony in plasma and skin of patients with cutaneous leishmaniasis \u2013 relationship with side effects after treatment with meglumine antimoniate"],"prefix":"10.1111","volume":"14","author":[{"given":"Diana Brito","family":"Da Justa Neves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa Dutra","family":"Caldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimunda Nonato Ribeiro","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004300100089"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1039\/b510088g"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2003.09.008"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612023396258"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822000000600004"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/clinchem\/36.4.680","article-title":"Retention of antimony in skin biopsies of leishmaniasis patients after treatment with N\u2010methylglucamine antimoniate","volume":"36","author":"Dorea JG","year":"1990","journal-title":"Clinical Chemistry"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2003.01169.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2005.04.020"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)80121-6"},{"key":"e_1_2_7_11_1","first-page":"133","article-title":"Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis","volume":"12","author":"Jaser MA","year":"1995","journal-title":"Pharmaceutical Research"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.516"},{"key":"e_1_2_7_13_1","first-page":"513","article-title":"Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis","volume":"17","author":"Kashani MN","year":"2007","journal-title":"European Journal of Dermatology"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2005.03.012"},{"key":"e_1_2_7_15_1","first-page":"272","volume":"91","author":"Lindoso JAL","year":"1996","journal-title":"Anti-leishmanial drug Glucantime\u00ae induces cell-mediated oxidative modifications of low density lipoprotein (LDL) Mem\u00f3rias do Instituto Oswaldo Cruz"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2005.11.018"},{"key":"e_1_2_7_17_1","first-page":"45","article-title":"Pancreatite: um dos efeitos adversos da terapia antimonial na leishmaniose","volume":"75","author":"Mattos MN","year":"2000","journal-title":"Anais Brasileiros de Dermatologia"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-001-1213-7"},{"key":"e_1_2_7_19_1","first-page":"499","article-title":"Adverse events related to systemic treatment using Glucantime for cutaneous leishmaniasis: a report from Tunisia","volume":"68","author":"Mlika BR","year":"2008","journal-title":"M\u00e9decine tropicale: revue du Corps de sant\u00e9 colonial"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1999.00769.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962005000300004"},{"key":"e_1_2_7_22_1","first-page":"51","article-title":"Estudo hospitalar da leishmaniose tegumentar americana (LTA): epidemiologia e tratamento","volume":"76","author":"Nogueira LSC","year":"2001","journal-title":"Anais Brasileiros de Dermatologia"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822005000300011"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822006000400001"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00188.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1997.57.651"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822003000300009"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-40422003000400018"},{"key":"e_1_2_7_29_1","unstructured":"Rede intergerencial de Informa\u00e7\u00f5es para a Sa\u00fade (RIPSA)(2008)http:\/\/wwwripsaorgbr\/fichasIDB\/levelphp?node=D&lang=pt assessed on February 2008."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-3623(97)00268-1"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822000000400009"},{"key":"e_1_2_7_32_1","first-page":"411","article-title":"Drug resistance mechanisms in clinical isolates of Leishmania donovani","volume":"123","author":"Singh N","year":"2006","journal-title":"The Indian Journal of Medical Research"},{"key":"e_1_2_7_33_1","unstructured":"World Health Organization(2008)Leishmaniasis: the disease and its epidemiology.http:\/\/wwwwhoint\/leishmaniasis\/en."}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-3156.2009.02408.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-3156.2009.02408.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T11:29:03Z","timestamp":1697282943000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-3156.2009.02408.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,5]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1365-3156.2009.02408.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-3156.2009.02408.x","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,5]]}}}